The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

It is well recognized that, in many cases, endometrial carcinoma is a well differentiated tumor bearing ... Supported in part by a National Cancer Institute research grant (C 2421).

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer. The OncoSignature multiplex ... which is a novel, differentiated WEE1/PKMYT1 ...

Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...

Cantor Fitzgerald analysts initiated coverage of Acrivon Therapeutics Inc (NASDAQ:ACRV) with an Overweight rating. The initiation comes with a positive outlook on the company's potential in the field ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

Role of laparoscopic & robotic surgery in oncology: Dr. Arvind Kumar Wednesday, February 5, 2025, 08:00 Hrs [IST] Advancements in surgical techniques ...

Eisai’s Lenvima was first approved by the FDA in February 2015 for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).